[go: up one dir, main page]

AR089324A1 - COMPOSITIONS, METHODS AND KITS FOR THE PREPARATION OF SEALED RECOMBINANT PROTEINS - Google Patents

COMPOSITIONS, METHODS AND KITS FOR THE PREPARATION OF SEALED RECOMBINANT PROTEINS

Info

Publication number
AR089324A1
AR089324A1 ARP120104817A ARP120104817A AR089324A1 AR 089324 A1 AR089324 A1 AR 089324A1 AR P120104817 A ARP120104817 A AR P120104817A AR P120104817 A ARP120104817 A AR P120104817A AR 089324 A1 AR089324 A1 AR 089324A1
Authority
AR
Argentina
Prior art keywords
recombinant proteins
kits
protein
compositions
preparation
Prior art date
Application number
ARP120104817A
Other languages
Spanish (es)
Inventor
Barnett Thomas
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of AR089324A1 publication Critical patent/AR089324A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99004—Beta-galactoside alpha-2,3-sialyltransferase (2.4.99.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procedimiento para alterar un patrón de sialilación de una o más proteínas recombinantes expresadas en una célula, en el que la célula está modificada genéticamente para expresar recombinantemente una a2,3-sialiltransferasa para sialilar la proteína. Este sistema de expresión incrementa la sialilación de la proteína que se expresa (FVIII - factor anti-hemofílico (AHF) ó factor de von Willebrand (vWF)), en particular la cantidad de un ácido siálico enlazado por a2,3 unido a la proteína. Composición. Célula. Método de tratamiento.Procedure for altering a sialylation pattern of one or more recombinant proteins expressed in a cell, in which the cell is genetically modified to recombinantly express an a2,3-sialyltransferase to sialylate the protein. This expression system increases the sialylation of the protein that is expressed (FVIII - anti-hemophilic factor (AHF) or von Willebrand factor (vWF)), in particular the amount of a sialic acid bound by a2.3 bound to the protein . Composition. Cell. Treatment method

ARP120104817A 2011-12-19 2012-12-19 COMPOSITIONS, METHODS AND KITS FOR THE PREPARATION OF SEALED RECOMBINANT PROTEINS AR089324A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161577291P 2011-12-19 2011-12-19

Publications (1)

Publication Number Publication Date
AR089324A1 true AR089324A1 (en) 2014-08-13

Family

ID=47681979

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104817A AR089324A1 (en) 2011-12-19 2012-12-19 COMPOSITIONS, METHODS AND KITS FOR THE PREPARATION OF SEALED RECOMBINANT PROTEINS

Country Status (4)

Country Link
AR (1) AR089324A1 (en)
AU (1) AU2012340501A1 (en)
UY (1) UY34527A (en)
WO (1) WO2013093760A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64664B1 (en) * 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc Optimized factor viii gene
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
EP3042952A1 (en) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
SG11201708754XA (en) 2015-05-22 2017-12-28 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
CA3005906A1 (en) 2015-11-19 2017-05-26 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
CA3010720A1 (en) 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
HRP20221089T1 (en) 2016-02-01 2022-11-25 Bioverativ Therapeutics Inc. Optimized factor viii genes
JP7252890B2 (en) 2016-11-11 2023-04-05 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト Truncated von Willebrand factor polypeptides for treating hemophilia
US11890327B2 (en) 2016-11-11 2024-02-06 CSL Behring Lengnau AG Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
JP2020530436A (en) 2017-06-22 2020-10-22 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト Regulation of FVIII immunogenicity by truncated VWF
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
KR20220029733A (en) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 truncated von Willebrand factor (VWF) to increase the in vitro stability of coagulation factor VIII
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
EP4171657A1 (en) 2020-06-24 2023-05-03 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US5149637A (en) 1987-04-06 1992-09-22 Scripps Clinic & Research Foundation Recombinant Factor VIIIC fragments
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
KR100482917B1 (en) 1996-01-23 2005-11-11 퀴아진 지노믹스, 인코포레이티드 Methods for determining the sequence of nucleic acid molecules and compositions for them
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
AT403765B (en) 1996-04-12 1998-05-25 Immuno Ag METHOD FOR PRODUCING A PREPARATION CONTAINING A HIGHLY CLEANED COMPLEX
US6120460A (en) 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
EP1000176A1 (en) 1997-07-22 2000-05-17 Rapigene, Inc. Computer method and system for correlating sequencing data by ms
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
SI1161548T2 (en) 1999-04-15 2010-02-26 Crucell Holland Bv Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
US20060099685A1 (en) * 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
EP1287010A1 (en) 2000-06-02 2003-03-05 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
WO2003054232A2 (en) 2001-12-13 2003-07-03 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
US7642078B2 (en) 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
TWI488640B (en) * 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 Pharmaceutical preparation
TWI532495B (en) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 Pharmaceutical preparation
US20110086362A1 (en) 2009-10-09 2011-04-14 Massachusetts Institute Of Technology High-Throughput Method for Quantifying Sialylation of Glycoproteins

Also Published As

Publication number Publication date
UY34527A (en) 2013-07-31
WO2013093760A2 (en) 2013-06-27
WO2013093760A3 (en) 2013-11-14
AU2012340501A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
AR089324A1 (en) COMPOSITIONS, METHODS AND KITS FOR THE PREPARATION OF SEALED RECOMBINANT PROTEINS
CL2018000238A1 (en) Peptide mixture (divisional application 201601405)
AR095660A1 (en) MANUFACTURING METHODS FOR CONTROLLING THE CONTENT OF LISIN C-TERMINAL, GALACTOSE AND SYNALIC ACID IN RECOMBINANT PROTEINS
BR112014019901A8 (en) RECOMBINANT FACTOR VIII PROTEINS
CY1122691T1 (en) SERUM ALBUMIN-BINDING PROTEINS
PE20130041A1 (en) FIBRONECTIN SCAFFOLDING DOMAIN PROTEINS THAT BIND INTERLEUKIN 23 (IL-23)
CL2012001258A1 (en) An isolated von willebrand factor (fvw) polypeptide comprising a factor viii (fviii) binding domain, wherein said polypeptide lacks some fvw domains, comprises an immunoglobulin fc amino acid sequence; composition and protein complex that comprises it; cell expressing said polypeptide; cell that expresses said protein complex; composition comprising the protein complex.
MX354555B (en) Growth hormone polypeptides and methods of making and using same.
PE20181206A1 (en) SPECIFIC LIVER CONSTRUCTIONS, FACTOR VIII EXPRESSION CASSETTES AND METHODS OF USE OF THESE
PE20141727A1 (en) COMPOSITIONS, USES AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS AND DISEASES
BR112015022558A2 (en) isolated nucleic acid sequence of the pcs1 promoter, expression construct or recombinant host cell comprising the nucleic acid sequence, stable cell culture of a plurality of said host cells, method for producing a protein of interest and use of an isolated sequence of nucleic acids comprising a promoter in a method for producing a protein of interest
GT201300295A (en) "COMPOSITIONS CONTAINING, METHODS THAT INVOLVE, AND USES OF DOLASTATIN DERIVATIVES UNITED TO NON-NATURAL AMINO ACIDS"
BR112015013311A2 (en) tolerance induction and factor 8 mutation repair
BRPI0609797B8 (en) improved nanobodies for the treatment of aggregation-mediated disorders
WO2015023891A3 (en) Factor viii-xten fusions and uses thereof
BR112014000466A2 (en) chimeric and hybrid factor viii polypeptides, methods of using them
BR112014012460A2 (en) recombinant proteins and their therapeutic uses
CL2009000123A1 (en) Humanized antibody or binding fragment thereof specific for von willebrand factor (vwf); coding nucleic acid; vector and host cells; method of producing said humanized antibody; composition comprising it; medical use thereof to treat a vwf-mediated disorder; non-therapeutic uses
IN2014DN09815A (en)
AR091647A1 (en) PURIFICATION OF IDURONATE-2-SULFATASE
EA201592022A1 (en) Fragmented by thrombinom LINKER, CONTAINING XTEN, AND ITS APPLICATION
EA201290565A1 (en) GETTING THE PROTEIN OF HEMAGGLUTININ-NEURAMINIDASE IN MICROWAVES
BR112013017367A2 (en) caracarp polypeptide, nucleic acid sequence, pharmaceutical composition and method for producing at least one carabin polypeptide
CO2017011431A2 (en) Variant epidermal growth factor receptor fusion proteins iii - mesothelin
EP2600894A4 (en) MODIFIED HEPATITIS C VIRUS PROTEINS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal